Speculating in Takeover Targets Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets

ULBI 5.640

-0.4%

10:45 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: richardred who wrote (2282)	7/23/2010 6:29:12 PM
From: richardred	Read Replies (3) of 7252

Just a thought on MRX. The latest press release about Sanofi-Aventis from CNBC is stating a possible Genzyme hook up. What about a smaller, 2 billion one like MRX? AGN has been mentioned several times, but it's more expensive given EBITDA to sales comparison. Sanofi makes a competing product called sculptra. It's in , but light in skin care. Fits right into the theme of the Chattem acquisition. sculptraaesthetic.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next